Answers are grounded in this paper and cite their sources.
Tumor microenvironment-driven immune evasion highlights therapeutic strategies and clinical trial pathways in HNSCC, indicating targeted immunotherapy may benefit specific patient groups.
The HNSCC TME is both a central barrier and an attractive therapeutic target. Embedding high-resolution TME profiling into clinical trials will be crucial to select TME-matched combinations and identify patient subsets most likely to derive durable benefit from immunotherapy.
No takes yet. Share an insight, caveat, or question.
Tinhofer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: